Literature DB >> 1361525

The erbB-3 gene in human pancreatic cancer.

N R Lemoine1, M Lobresco, H Leung, C Barton, C M Hughes, S A Prigent, W J Gullick, G Klöppel.   

Abstract

Abnormalities of the type 1 growth factor receptor family have been implicated in the pathogenesis of pancreatic cancer. There is evidence for a potential autocrine loop involving overexpression of the epidermal growth factor (EGF) receptor and its ligands, as well as overexpression of the erbB-2 receptor. A third member of this receptor family, erbB-3, has recently been recognized and found to be abnormally expressed in some types of human cancer. In this study we show that overexpression of the erbB-3 protein occurs very frequently in carcinoma of the exocrine pancreas and also in chronic pancreatitis. We found no evidence of amplification or rearrangement of the erbB-3 gene by Southern blot analysis of DNA from pancreatic cancer cells lines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1361525     DOI: 10.1002/path.1711680305

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  20 in total

1.  ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.

Authors:  J Spencer Liles; Juan Pablo Arnoletti; Ching-Wei D Tzeng; J Harrison Howard; Andrew V Kossenkov; Peter Kulesza; Martin J Heslin; Andrey Frolov
Journal:  Cancer Biol Ther       Date:  2010-09-30       Impact factor: 4.742

2.  Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.

Authors:  Chunrong Li; Toni M Brand; Mari Iida; Shyhmin Huang; Eric A Armstrong; Albert van der Kogel; Deric L Wheeler
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

3.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

4.  bax, but not bcl-2, influences the prognosis of human pancreatic cancer.

Authors:  H Friess; Z Lu; H U Graber; A Zimmermann; G Adler; M Korc; R M Schmid; M W Büchler
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

Review 5.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

6.  Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models.

Authors:  Andrea Wang-Gillam; Kian-Huat Lim; Hongmei Jiang; Mai Xu; Lin Li; Patrick Grierson; Paarth Dodhiawala; Maureen Highkin; Daoxiang Zhang; Qiong Li
Journal:  Mol Cancer Ther       Date:  2018-07-31       Impact factor: 6.261

Review 7.  The type I growth factor receptors in human breast cancer.

Authors:  T Rajkumar; W J Gullick
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

8.  Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis.

Authors:  D Birk; F Gansauge; S Gansauge; A Formentini; A Lucht; H G Beger
Journal:  Int J Pancreatol       Date:  1999-04

9.  Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells.

Authors:  T Oikawa; J Hitomi; A Kono; E Kaneko; K Yamaguchi
Journal:  Int J Pancreatol       Date:  1995-08

Review 10.  Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors.

Authors:  H Friess; P Berberat; M Schilling; J Kunz; M Korc; M W Büchler
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.